{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:13:57Z","timestamp":1789182837624,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015629","name":"Chinook Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016185","name":"Aimmune Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtho.2021.05.003","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T03:04:10Z","timestamp":1621998250000},"page":"1733-1744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5465-7698","authenticated-orcid":false,"given":"Abdul Rahman","family":"Jazieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin Cem","family":"Onal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Shao Weng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Huggenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung-Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.05.003_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2021.05.003_bib2","first-page":"199","article-title":"AS1404-201 Study Group Investigators. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data","volume":"2","author":"McKeage","year":"2010","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2021.05.003_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for Revision of the TNM Stage Groupings in the Forthcoming (eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11864-018-0556-7","article-title":"Immune checkpoint inhibitors in early-stage and locally advanced non-small cell lung cancer","volume":"19","author":"Puri","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib5","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer Guidelines. NCCN.org. Accessed June 11, 2021."},{"key":"10.1016\/j.jtho.2021.05.003_bib6","doi-asserted-by":"crossref","first-page":"190024","DOI":"10.1183\/16000617.0024-2019","article-title":"Interdisciplinary multimodality management of stage III nonsmall cell lung cancer","volume":"28","author":"Huber","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jtho.2021.05.003_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"10.1016\/j.jtho.2021.05.003_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non\u2013small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib9","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/88.17.1210","article-title":"Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial","volume":"88","author":"Dillman","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2021.05.003_bib10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2021.05.003_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2017.11.135","article-title":"The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer","volume":"13","author":"Miller","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/JTO.0b013e31820eed00","article-title":"Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer","volume":"6","author":"Davidoff","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib14","first-page":"348","article-title":"Accelerated dose escalation with proton beam therapy for non-small cell lung cancer","volume":"6","author":"Gomez","year":"2014","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2021.05.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib16","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtho.2021.05.003_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2013.0084","article-title":"Non-small cell lung cancer, version 2.2013","volume":"11","author":"Ettinger","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"suppl 6","key":"10.1016\/j.jtho.2021.05.003_bib19","doi-asserted-by":"crossref","first-page":"vi89","DOI":"10.1093\/annonc\/mdt241","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Vansteenkiste","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.radonc.2014.07.014","article-title":"Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer","volume":"112","author":"Ezer","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2020.05.033","article-title":"Ten-year patient journey of stage III non-small cell lung cancer patients: a single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.05.003_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdj117","article-title":"Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients","volume":"17","author":"Aup\u00e9rin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.05.003_bib24","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.05.003_bib26","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00259-019-04421-5","article-title":"Introducing FDG PET\/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial","volume":"46","author":"Konert","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2021.05.003_bib27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jtho.2019.04.005","article-title":"Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy","volume":"14","author":"Moore","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2021.05.003_bib28","article-title":"Trimodality therapy in the treatment of stage IIIA non-small cell\u00a0lung cancer (NSCLC): analysis of the National Cancer Database","volume":"33","author":"Behera","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.lungcan.2014.06.005","article-title":"Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function","volume":"85","author":"Dickhoff","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.05.003_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12032-019-1249-1","article-title":"Real-world outcomes in patients with unresected stage III non-small cell lung cancer","volume":"36","author":"Ryan","year":"2019","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib31","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.05.003_bib32","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2021.05.003_bib33","article-title":"Neoadjuvant chemo\/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): a phase II multicenter exploratory study\u2014NADIM study-SLCG","volume":"36","author":"Provencio-Pulla","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2021.05.003_bib34","article-title":"SAKK 16\/14: anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)\u2014a multicenter single-arm phase II trial","volume":"38","author":"Rothschild","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.05.003_bib35","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421021742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421021742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:46:28Z","timestamp":1761561988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421021742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1556086421021742"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.05.003","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}